STOCK TITAN

Alkermes to Participate in the Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) to Participate in Fireside Chat at Jefferies London Healthcare Conference on Nov. 14, 2023
Positive
  • None.
Negative
  • None.

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14, 2023 at 12:00 p.m. ET (5:00 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-jefferies-london-healthcare-conference-301980646.html

SOURCE Alkermes plc

Alkermes plc (Nasdaq: ALKS) will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 14, 2023.

The live webcast can be accessed under the Investors tab on www.alkermes.com on Nov. 14, 2023 at 12:00 p.m. ET (5:00 p.m. GMT) and will be archived for 14 days.
Alkermes plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.